Netvax

RSS

adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Netvax has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 11/06/2014

Authorisation details

Product details
Name
Netvax
Agency product number
EMEA/V/C/000134
Active substance
Clostridium-perfringens-type-A alpha toxoid
International non-proprietary name (INN) or common name
adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens
Species
Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AB08
Publication details
Marketing-authorisation holder
Intervet International BV
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
15/04/2009
Contact address
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

18/09/2013 Netvax - EMEA/V/C/000134 - IB/0006

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

IMMUNOLOGICALS FOR AVES

Therapeutic indication

For the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.

To reduce mortality and the incidence and severity of lesions caused by Clostridium-perfringens-type-A-induced necrotic enteritis. Efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.

The onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.

The duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.

Assessment history

How useful was this page?

Add your rating